



Press Release

Lupin receives USFDA Approval for Topiramate Tablets

BSE: 500257	NSE: LUPIN	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
-------------	------------	---------------------	----------------------

Mumbai, India, May 30, 2008 –Lupin Ltd. (Lupin), announced today that it has received tentative approval for the Company’s Abbreviated New Drug Application (ANDA) for Topiramate tablets, 25 mg, 50 mg, 100 mg and 200 mg from the U.S. Food and Drug Administration (US FDA).

Lupin’s Topiramate tablets are the AB-rated generic equivalent of Ortho-McNeil’s TOPAMAX® tablets, indicated for the treatment of seizures. The brand product had annual sales of approximately \$2.2 billion for the twelve months ended March 2008, based on IMS Health sales data.

Commenting on the approval, Dr Kamal Sharma, Managing Director, Lupin, said, “Lupin is pleased to receive this approval that will enable the Company to offer Topiramate tablets as an affordable generic alternative that will have a measurable impact on the U.S. healthcare system.”

The product will be introduced in the market through LPIs strong network of national wholesalers and drug stores post patent expiry in Sep 2008. This will strengthen Lupin’s presence in the CNS segment.

With the approval of Topiramate tablets the cumulative ANDA approvals stands at 29 (including 3 tentative approvals) with 34 pending approvals from the USFDA.

About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company positioned amongst the top six pharmaceutical companies in India, has secured a global leadership position in Anti-TB and Cephalosporins. It has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma ,CNS and NSAIDs segments.

The Company’s R&D endeavors have resulted in significant progress in its NCE program. The Company’s foray into New Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.

For the financial year ended March 2008, Lupin's Revenues and Profit after Tax were Rs.27,730 million (US\$ 694 million) and Rs.4,083 million (US\$ 102 million) respectively.

Lupin Pharmaceuticals, Inc.(LPI) is the wholly owned subsidiary of Lupin Limited in the US. LPI through its sales and marketing headquarters in Baltimore, Maryland, is dedicated to delivering high-quality, affordable generic medicines trusted by healthcare professionals and patients across geographies. For more information, visit <http://www.lupinpharmaceuticals.com>.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.

*Topamax® is a registered trademark of Ortho-McNeil Neurologics, Inc.

For More Information :

India Contact

Lupin Ltd.

Seema Ahuja

Head, Corporate Communications

Ph: +91-9920042046

Email:seemaahuja@lupinpharma.com